News

The new meta-analysis included data from nearly 18,000 patients. Overall, patient outcomes were quite similar for patients who did and did not undergo beta-blocker therapy.

GE HealthCare

The Chicago-based imaging systems manufacturer said it plans to pay the purchase price in cash, believing the acquisition demonstrates its “continued commitment to cloud-enabled and AI-powered solutions.” 

A majority of medical devices involved in Class I recalls were never required by the U.S. Food and Drug Administration (FDA) to undergo premarket or postmarket clinical testing, according to new research published in Annals of Internal Medicine.[1]

A clinical trial focused on patients with HFpEF is expected to be completed by July 2026.

Boston Scientific ACURATE neo2 aortic valve system self-expanding TAVR valve

Boston Scientific stopped selling its Acurate TAVR systems after they underperformed in a few key trials and failed to gain FDA approval. Was it the right call?

Hexoskin Medical System

According to Hexoskin, the newly cleared technology offers significant value for hospitals and health systems as well as researchers conducting clinical trials. 

 Emily Sedgwick, MD, MBA

The breast screening provider has picked Emily Sedgwick, MD, MBA, to fill the key role and is opening new centers in Texas and Colorado. 

allstate

Filed in a Texas federal court, the complaint names Prime Imaging Partners and Memorial MRI & Diagnostic among numerous defendants, with the alleged auto-injury scheme occurring from 2019-2023. 

piedmont

The private equity-backed, Tennessee-based imaging group is expanding in Georgia and Missouri through partnerships with Piedmont and BJC HealthCare, respectively. 

vituity

Northern California-based Vituity, which is led and owned by doctors, said it has reached a deal to partner with Focused Medical Imaging. 

UCLA Health

“Becoming an independent department elevates this work and strengthens UCLA’s role in shaping the future of precision health," said the department's new acting chairman. 

RapidAI's opportunistic aortic management tool earns FDA clearance

The solution can assess the aorta on any CT scan that offers visualization of it, including post-treatment and unenhanced noncontrast studies. 

physician tracking patient data and reporting on outcomes

In a report, News Center Maine spoke to a personal injury attorney who said she often receives numerous copies of medical records for her clients, each with its own fee. She said she is glad someone decided to sue over the issue, which may violate state law capping patient record-sharing costs.

Around the web

The new meta-analysis included data from nearly 18,000 patients. Overall, patient outcomes were quite similar for patients who did and did not undergo beta-blocker therapy.

The Chicago-based imaging systems manufacturer said it plans to pay the purchase price in cash, believing the acquisition demonstrates its “continued commitment to cloud-enabled and AI-powered solutions.” 

A clinical trial focused on patients with HFpEF is expected to be completed by July 2026.